PI
AUPH icon

PEAK6 Investments’s Aurinia Pharmaceuticals AUPH Stock Holding History

PEAK6 Investments’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-72,239
Closed -$649K – 4017
2023
Q4 		$649K Buy
72,239
+7,207
+11% +$59.4K ﹤0.01% 2428
2023
Q3 		$505K Buy
65,032
+2,255
+4% +$22.1K ﹤0.01% 2386
2023
Q2 		$608K Buy
62,777
+4
+0% +$42 ﹤0.01% 2055
2023
Q1 		$688K Buy
62,773
+5,602
+10% +$49.4K ﹤0.01% 2136
2022
Q4 		$247K Buy
57,171
+33,005
+137% +$192K ﹤0.01% 3123
2022
Q3 		$182K Sell
24,166
-38,611
-62% -$334K ﹤0.01% 3738
2022
Q2 		$608K Buy
62,777
+38,613
+160% +$432K ﹤0.01% 2056
2022
Q1 		$299K Buy
24,164
+15,189
+169% +$235K ﹤0.01% 3571
2021
Q4 		$205K Buy
+8,975
New +$213K ﹤0.01% 3985

Other funds holding AUPH

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PEAK6 Investments's AUPH Position: Q1 2024 in Review

PEAK6 Investments sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2024, closing a stake of 72,239 shares — an estimated $649K sold.

PEAK6 Investments first reported a position in AUPH in Q4 2021 and held it in 9 quarters. The position peaked at $688K in Q1 2023. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

  • PEAK6 Investments reported no remaining Aurinia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • PEAK6 Investments sold 72,239 Aurinia Pharmaceuticals shares in Q1 2024, an estimated $649K.
  • PEAK6 Investments first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • PEAK6 Investments's Aurinia Pharmaceuticals position peaked at $688K in Q1 2023.
  • 179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.